Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Short term Debt (2024 - 2025)

Viridian Therapeutics, Inc.\DE has reported Short term Debt over the past 3 years, most recently at $8.4 million for Q2 2025.

  • Quarterly results put Short term Debt at $8.4 million for Q2 2025, up 184.58% from a year ago — trailing twelve months through Jun 2025 was $8.4 million (up 184.58% YoY), and the annual figure for FY2014 was $1.0 million, changed.
  • Short term Debt for Q2 2025 was $8.4 million at Viridian Therapeutics, Inc.\DE, up from $3.0 million in the prior quarter.
  • Over the last five years, Short term Debt for VRDN hit a ceiling of $8.4 million in Q2 2025 and a floor of $3.0 million in Q2 2024.